Overview

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Status:
Recruiting

Trial end date:
2024-05-09

Target enrollment:

Participant gender:

Summary

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborator:

AstraZeneca